Evidence map›Paper›PMID 40196906›Full record

ArticleNanomedicine (London, England)2025

Synergistic RNA particles for spontaneous and specific cancer targeting but low toxicity due to motility and deformation.

Daniel W Binzel, Peixuan Guo

Abstract readEditorial
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel W BinzelCenter for RNA Nanobiotechnology and Nanomedicine, Division of Pharmaceutics and Pharmacology, College of Pharmacy, and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Peixuan GuoCenter for RNA Nanobiotechnology and Nanomedicine, Division of Pharmaceutics and Pharmacology, College of Pharmacy, and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.

Funding

Mechanism and approach to inactivate mutant KRAS of lung metastatic colon cancer by RNA-ligand-displaying exosome to co-deliver dCas9--gRNA ribonucleoprotein complex and KRAS siRNAR01CA293945 · NCI · OHIO STATE UNIVERSITY · PI BIN GUO, PEIXUAN GUO · 2024 to 2026
$2.4M
TNBC Ligand-displaying Exosomes Using RNA Nanotechnology for Targeted Cytosol Delivery of RNAi without Endosome EntrapmentR01CA257961 · NCI · OHIO STATE UNIVERSITY · PI BINZEL, DANIEL W, SHU, DAN · 2021 to 2025
$1.7M
NCI NIH HHS R01 CA257961NCI NIH HHS R01 CA293945
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer targetingdeformable RNAfavorable biodistributionnanoparticle stabilityRNA deliveryRNA nanotechnologyRNA therapeutics

Identifiers

PMID40196906
PMCPMC12233875

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.